(Q47333601)

English

Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus

scientific article published in July 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/16776749

Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus (English)

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/16776749

type 2 diabetes

0 references

0 references

1 reference

based on heuristic

inferred from title

author name string

Ratner RE

1

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/16776749

Maggs D

2

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/16776749

Nielsen LL

3

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/16776749

Stonehouse AH

4

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/16776749

Poon T

5

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/16776749

Zhang B

6

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/16776749

Bicsak TA

7

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/16776749

Brodows RG

8

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/16776749

Kim DD

9

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/16776749

publication date

1 July 2006

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/16776749

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/16776749

8

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/16776749

4

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/16776749

419-428

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/16776749

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00589.X

21 January 2018

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00589.X

21 January 2018

Pharmacologic therapy for type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00589.X

21 January 2018

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00589.X

21 January 2018

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00589.X

21 January 2018

Metformin: An Update

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00589.X

21 January 2018

Clinical practice. Initial management of glycemia in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00589.X

21 January 2018

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00589.X

21 January 2018

Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00589.X

21 January 2018

Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00589.X

21 January 2018

Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00589.X

21 January 2018

Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00589.X

21 January 2018

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00589.X

21 January 2018

Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00589.X

21 January 2018

Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00589.X

21 January 2018

Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00589.X

21 January 2018

Optimal glycemic control in type 2 diabetes mellitus: fasting and postprandial glucose in context

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00589.X

21 January 2018

Pharmacokinetics, pharmacodynamics, and dose-response relationship of repaglinide in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00589.X

21 January 2018

Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00589.X

21 January 2018

Repaglinide versus glyburide: a one-year comparison trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00589.X

21 January 2018

The dyslipidemia of diabetes mellitus: giving triglycerides and high-density lipoprotein cholesterol a higher priority?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00589.X

21 January 2018

Avandamet: combined metformin-rosiglitazone treatment for insulin resistance in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00589.X

21 January 2018

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00589.X

21 January 2018

Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00589.X

21 January 2018

Identifiers

10.1111/J.1463-1326.2006.00589.X

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/16776749

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/16776749

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47333601&oldid=2152408859"